Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin

Journal of Diabetes

Volumn 9, Issue 7, 2017, Pages 667-676

  Ba, Jianming ^a   Han, Ping ^b   Yuan, Guoyue ^c   Mo, Zhaohui ^d   Pan, Changyu ^a   Wu, Fan ^e   Xu, Lei ^e   Hanson, Mary E ^e   Engel, Samuel S ^e   Shankar, R Ravi ^e  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Shengjing Hospital of China Medical University   (China)

^c AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

China; HbA1c; hypoglycemia; sitagliptin; sulfonylurea

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CHINA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; ETHNOLOGY; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHINA; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84992643619     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12456     Document Type: Article

References (24)

1. International Diabetes Federation (IDF). IDF Diabetes Atlas, 7th edn. Brussels, Belgium, International Diabetes Federation, 2015.Available from: http://www.diabetesatlas.org, accessed 31 May 2016
2. Xu Y, Wang L, He J et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310: 948–959.
3. American Diabetes Association. Standards of Care in Diabetes – 2015. J Clin Applied Res Educ. 2015; 38(Suppl. 1): S1–S93.
4. International Diabetes Federation (IDF). IDF Diabetes Atlas, 6th edn. Brussels, Belgium, IDF, 2014.
5. Handelsman Y, Bloomgarden ZT, Grunberger G et al. American Association of Clinical Endocrinologists and American College of Endocrinology: Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015; 21: 1–87.
6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281: 2005–2012.
7. Holman RR. Long-term efficacy of sulfonylureas: A United Kingdom Prospective Diabetes Study perspective. Metabolism. 2006; 55(Suppl. 1): S2–S5.
8. Ashcroft FM. Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res. 1996; 28: 456–463.
9. Hundal RS, Krssak M, Dufour S et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000; 49: 2063–2069.
10. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998; 338: 867–872.
11. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000; 321: 405–412.
12. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55: 1577–1596.
13. Mohan V, Yang W, Son HY et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract. 2009; 83: 106–116.
14. Yang W, Guan Y, Shentu Y et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes. 2012; 4: 227–237.
15. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007; 9: 733–745.
16. Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankya, Series B. 2000; 62: 134–148.
17. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985; 4: 213–226.
18. Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: An 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2012; 34: 1909–1919.
19. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial. Int J Clin Pract. 2009; 63: 1395–1406.
20. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009; 11: 167–176.
21. Moses RG, Kalra S, Brook D et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab. 2014; 16: 443–450.
22. Moses RG, Round E, Shentu Y et al. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes. 2015. DOI:10.1111/1753-0407.12351.
23. Cho YM. Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig. 2015; 6: 495–507.
24. Yabe D, Hitoshi K, Iwasaki M, Seino Y. Why are incretin-based therapies more efficient in East Asians? Perspectives from the pathophysiology of type 2 diabetes and East Asian dietary habits. Eur Med J Diabetes. 2015; 3: 57–65.